Xiaojin Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaojin Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Xiangqian Zhang
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
3 shared publicationsDandan Zhu
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publicationsHanyang Su
Department of Respiratory Medicine & Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, China
2 shared publicationsJie Wang
Department of Physiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China
2 shared publicationsYe Zhang
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications- Huajun Zhang
Department of Ultrasonic Imaging, Xiangya Hospital, Central South University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51036
Shared genetic architecture between constipation and aging-related phenotypes
While the frequency of constipation increases sharply with age, the genetic links between constipation and aging-related phenotypes remain largely unexplored. So far, research has typically focused only on individual characteristics while neglecting broader genetic connections. In this study, we evaluated the shared genetic architecture of constipation and aging-related phenotypes in order to better understand the causes of aging-related intestinal dysfunction. Using publicly available genome-wide association study summary statistics, we developed a multi-stage analysis pipeline to identify common signals at the variation and genetic levels. We studied 4 aging-related phenotypes: frailty index (FI), telomere length, facial aging and GrimAge acceleration. Our approach combines linkage disequilibrium score regression and high-definition likelihood with Pleiotropy Analysis under Composite Null Hypothesis, functional mapping and annotation and Bayesian colocalization to identify pleiotropic loci, followed by tissue-specific mapping via Multi-marker Analysis of GenoMic Annotation and stratified linkage disequilibrium score regression. Constipation showed a moderate positive genetic correlation with FI in both linkage disequilibrium score regression and high-definition likelihood. The inverse correlation with TL was weak and method-dependent. No significant genome-wide genetic correlation was detected with facial aging or GrimAge acceleration. Multi-layer locus mapping and gene-based analyses prioritized several candidate genes, including MSL2 , STAG1 , and SRSF9, through different combinations of association-based evidence. However, no gene showed multiple-testing-corrected summary-data-based Mendelian randomization evidence shared between constipation and any of the 4 aging-related phenotypes. Multi-marker Analysis of GenoMic Annotation suggested cerebellar enrichment for genes associated with the constipation–FI pair, whereas stratified linkage disequilibrium score regression identified broader central nervous system enrichment for FI but no significant cell-type enrichment for constipation. These findings support a shared genetic component between constipation and selected aging-related phenotypes and provide candidate loci, genes and tissues for further functional investigation.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51036
Open AccessShared genetic architecture between constipation and aging-related phenotypes
While the frequency of constipation increases sharply with age, the genetic links between constipation and aging-related phenotypes remain largely unexplored. So far, research has typically focused only on individual characteristics while neglecting broader genetic connections. In this study, we evaluated the shared genetic architecture of constipation and aging-related phenotypes in order to better understand the causes of aging-related intestinal dysfunction. Using publicly available genome-wide association study summary statistics, we developed a multi-stage analysis pipeline to identify common signals at the variation and genetic levels. We studied 4 aging-related phenotypes: frailty index (FI), telomere length, facial aging and GrimAge acceleration. Our approach combines linkage disequilibrium score regression and high-definition likelihood with Pleiotropy Analysis under Composite Null Hypothesis, functional mapping and annotation and Bayesian colocalization to identify pleiotropic loci, followed by tissue-specific mapping via Multi-marker Analysis of GenoMic Annotation and stratified linkage disequilibrium score regression. Constipation showed a moderate positive genetic correlation with FI in both linkage disequilibrium score regression and high-definition likelihood. The inverse correlation with TL was weak and method-dependent. No significant genome-wide genetic correlation was detected with facial aging or GrimAge acceleration. Multi-layer locus mapping and gene-based analyses prioritized several candidate genes, including MSL2 , STAG1 , and SRSF9, through different combinations of association-based evidence. However, no gene showed multiple-testing-corrected summary-data-based Mendelian randomization evidence shared between constipation and any of the 4 aging-related phenotypes. Multi-marker Analysis of GenoMic Annotation suggested cerebellar enrichment for genes associated with the constipation–FI pair, whereas stratified linkage disequilibrium score regression identified broader central nervous system enrichment for FI but no significant cell-type enrichment for constipation. These findings support a shared genetic component between constipation and selected aging-related phenotypes and provide candidate loci, genes and tissues for further functional investigation.
- 8 October 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (11) , 320
A20 promotes OPN ubiquitination and degradation to inhibit cell growth and invasion in human hepatocellular carcinoma
- 8 October 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (11) , 320
A20 promotes OPN ubiquitination and degradation to inhibit cell growth and invasion in human hepatocellular carcinoma
- Open Access
- 7 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-18
ITGAV as a promising diagnostic, immunological, and prognostic biomarker in pan-cancer
Integrin αV (ITGAV) plays a key role in cell adhesion, migration, and immune regulation, and is implicated in tumor progression. However, its comprehensive expression profile and functional relevance across different cancers remain poorly understood. We conducted an integrative pan-cancer analysis of ITGAV using data from TCGA, GTEx, CCLE, and other public databases. Expression, diagnostic value (via ROC analysis), and prognostic significance (via Cox and Kaplan–Meier analyses of OS, DSS, PFS, and DFS) were assessed. We further explored ITGAV’s correlation with immune cell infiltration and immune-related genes, its predictive role in immunotherapy response based on immunophenoscore (IPS), and its drug-binding potential through molecular docking. (1) ITGAV was significantly overexpressed in multiple cancer types including LIHC, COAD, and STAD. (2) ROC analysis confirmed its strong diagnostic value, particularly in HNSC, UCEC, and ESCA. (3) High ITGAV expression was associated with poorer survival outcomes in most cancers, while a protective role was observed in KIRC. (4) ITGAV expression was positively correlated with immune cell infiltration and co-expressed with immune-activating and immunosuppressive genes. (5) The expression level of ITGAV correlates with the IPS score, suggesting its predictive value for the benefit of immunotherapy. (6) Molecular docking identified strong binding affinities between ITGAV and six candidate compounds, including gemcitabine and pioglitazone. Our findings demonstrate that ITGAV is a promising biomarker for diagnosis, prognosis, and immunotherapy prediction across cancers. Its immunological associations and druggability highlight its potential as a candidate therapeutic target.
- 7 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-18
Open AccessITGAV as a promising diagnostic, immunological, and prognostic biomarker in pan-cancer
Integrin αV (ITGAV) plays a key role in cell adhesion, migration, and immune regulation, and is implicated in tumor progression. However, its comprehensive expression profile and functional relevance across different cancers remain poorly understood. We conducted an integrative pan-cancer analysis of ITGAV using data from TCGA, GTEx, CCLE, and other public databases. Expression, diagnostic value (via ROC analysis), and prognostic significance (via Cox and Kaplan–Meier analyses of OS, DSS, PFS, and DFS) were assessed. We further explored ITGAV’s correlation with immune cell infiltration and immune-related genes, its predictive role in immunotherapy response based on immunophenoscore (IPS), and its drug-binding potential through molecular docking. (1) ITGAV was significantly overexpressed in multiple cancer types including LIHC, COAD, and STAD. (2) ROC analysis confirmed its strong diagnostic value, particularly in HNSC, UCEC, and ESCA. (3) High ITGAV expression was associated with poorer survival outcomes in most cancers, while a protective role was observed in KIRC. (4) ITGAV expression was positively correlated with immune cell infiltration and co-expressed with immune-activating and immunosuppressive genes. (5) The expression level of ITGAV correlates with the IPS score, suggesting its predictive value for the benefit of immunotherapy. (6) Molecular docking identified strong binding affinities between ITGAV and six candidate compounds, including gemcitabine and pioglitazone. Our findings demonstrate that ITGAV is a promising biomarker for diagnosis, prognosis, and immunotherapy prediction across cancers. Its immunological associations and druggability highlight its potential as a candidate therapeutic target.
- Open Access
- 22 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-18
Integrative analysis of single-cell and transcriptome sequencing with experimental validation reveals PKHD1L1 as a novel biomarker in lung adenocarcinoma
Polycystic kidney and hepatic disease 1-like protein 1 (PKHD1L1) is predicted to encode a large type I transmembrane protein involved in hearing transmission and mediating cellular immunity under physiological conditions. However, its role in cancer progression, especially in lung adenocarcinoma (LUAD), has not been fully elucidated. In this study, we observed significantly lower expression of PKHD1L1 in LUAD tissues than in normal lung tissues on the basis of the integration of public datasets from the TCGA and GEO cohorts. Furthermore, we found that low PKHD1L1 expression was a strong predictor of poor prognosis in patients with LUAD. Pathway enrichment analyses revealed that PKHD1L1 is associated primarily with asthma and multiple immune processes. Through meticulous analysis of immune cell infiltrates and single-cell datasets, we discerned a notable correlation between the expression of PKHD1L1 and the presence of B cells, with a particularly strong association observed in plasma cells. This finding led us to believe that the role of PKHD1L1 may extend beyond its previously reported involvement in cellular immunity, potentially impacting humoral immunity as well. In vitro experiments revealed that the over-expression of PKHD1L1 significantly inhibited the proliferation and migration ability of LUAD cell lines. These findings suggest that PKHD1L1 is an important prognostic indicator and a potential therapeutic target for LUAD.
- 22 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-18
Open AccessIntegrative analysis of single-cell and transcriptome sequencing with experimental validation reveals PKHD1L1 as a novel biomarker in lung adenocarcinoma
Polycystic kidney and hepatic disease 1-like protein 1 (PKHD1L1) is predicted to encode a large type I transmembrane protein involved in hearing transmission and mediating cellular immunity under physiological conditions. However, its role in cancer progression, especially in lung adenocarcinoma (LUAD), has not been fully elucidated. In this study, we observed significantly lower expression of PKHD1L1 in LUAD tissues than in normal lung tissues on the basis of the integration of public datasets from the TCGA and GEO cohorts. Furthermore, we found that low PKHD1L1 expression was a strong predictor of poor prognosis in patients with LUAD. Pathway enrichment analyses revealed that PKHD1L1 is associated primarily with asthma and multiple immune processes. Through meticulous analysis of immune cell infiltrates and single-cell datasets, we discerned a notable correlation between the expression of PKHD1L1 and the presence of B cells, with a particularly strong association observed in plasma cells. This finding led us to believe that the role of PKHD1L1 may extend beyond its previously reported involvement in cellular immunity, potentially impacting humoral immunity as well. In vitro experiments revealed that the over-expression of PKHD1L1 significantly inhibited the proliferation and migration ability of LUAD cell lines. These findings suggest that PKHD1L1 is an important prognostic indicator and a potential therapeutic target for LUAD.
- 5 December 2022
- Published by Elsevier in Life Sciences
- Vol. 312, 121266
DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway
- 5 December 2022
- Published by Elsevier in Life Sciences
- Vol. 312, 121266
DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway